JAK2 is an inclusion criterion in 10 clinical trials for acute lymphoblastic leukemia, of which 9 are open and 1 is closed. Of the trials that contain JAK2 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].

JAK2 is an inclusion criterion in 5 clinical trials for acute myeloid leukemia, of which 5 are open and 0 are closed. Of the trials that contain JAK2 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

JAK2 is an inclusion criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain JAK2 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [4].

JAK2 is an inclusion criterion in 4 clinical trials for myelodysplastic syndromes, of which 3 are open and 1 is closed. Of the trials that contain JAK2 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (0 open), and 2 are phase 2 (2 open) [4].

JAK2 is an inclusion criterion in 3 clinical trials for essential thrombocythemia, of which 0 are open and 3 are closed. Of the trials that contain JAK2 status and essential thrombocythemia as inclusion criteria, 1 is phase 1/phase 2 (0 open), 1 is phase 2 (0 open), and 1 is phase 3 (0 open) [4].

JAK2 is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 1 is open and 2 are closed. Of the trials that contain JAK2 status and malignant solid tumor as inclusion criteria, 3 are phase 2 (1 open) [4].

JAK2 is an inclusion criterion in 3 clinical trials for polycythemia vera, of which 0 are open and 3 are closed. Of the trials that contain JAK2 status and polycythemia vera as inclusion criteria, 1 is phase 1/phase 2 (0 open), 1 is phase 2 (0 open), and 1 is phase 3 (0 open) [4].

JAK2 is an inclusion criterion in 2 clinical trials for mantle cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain JAK2 status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].

JAK2 is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain JAK2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

JAK2 is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 1 is open and 1 is closed. Of the trials that contain JAK2 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (0 open) [4].

JAK2 is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain JAK2 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [4].

JAK2 is an inclusion criterion in 2 clinical trials for primary myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain JAK2 status and primary myelofibrosis as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for lymphoproliferative disorder, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and lymphoproliferative disorder as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for polycythemia vera, post-polycythemic myelofibrosis phase, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and polycythemia vera, post-polycythemic myelofibrosis phase as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for primary cutaneous T-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and primary cutaneous T-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

JAK2 is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 0 are open and 1 is closed. Of the trial that contains JAK2 status and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 1 (0 open) [4].